西黄丸/胶囊辅助治疗乳腺癌的有效性和安全性的Meta分析  

Meta-Analysis on Efficacy and Safety of Xihuang Pills/Capsules in Adjuvant Treatment of Breast Cancer

作　　者：李会琴 姚丽鸽[1] 张柳艳 王莹杰 李佳音 LI Huiqin;YAO Lige;ZHANG Liuyan;WANG Yingjie;LI Jiayin(Dept.of Medical Oncology,Zhengzhou Third People’s Hospital,Zhengzhou 450000,China)

机构地区：[1]郑州市第三人民医院肿瘤内科,郑州450000

出　　处：《中国医院用药评价与分析》2023年第10期1241-1246,共6页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:评价西黄丸/胶囊在临床上辅助治疗乳腺癌的有效性和安全性,以期为临床治疗乳腺癌提供新思路。方法:在PubMed、Embase、the Cochrane Library、中国知网、中国生物医学文献服务系统、万方数据库和维普数据库等数据库中检索自建库以来至2022年12月2日关于西黄丸/胶囊治疗乳腺癌的随机对照试验文献,对检索出的文献进行筛选和数据提取,并使用RevMan 5.4软件进行Meta分析。结果:共纳入12项研究,涉及1260例患者,其中常规治疗+西黄丸/胶囊组637例患者,常规治疗组623例患者。Meta分析结果显示,与常规治疗组比较,常规治疗+西黄丸/胶囊组患者的治疗有效率更高,生活质量评分(卡诺夫斯凯计分、FACT-B评分)更高,免疫细胞指标CD3^(+)、CD4^(+)和CD4^(+)/CD8^(+)水平更高,肿瘤标志物中癌胚抗原(CEA)、糖类抗原153(CA153)和糖类抗原125(CA125)水平更低,差异均有统计学意义(P<0.05);两组患者免疫细胞指标CD8^(+)水平的差异无统计学意义(P>0.05)。安全性方面,常规治疗+西黄丸/胶囊组患者的白细胞减少、血小板减少、胃肠道反应、恶心呕吐和肝肾功能异常等发生情况少于常规治疗组,差异均有统计学意义(P<0.05);但两组患者骨髓抑制发生情况的差异无统计学意义(P>0.05)。结论:西黄丸作为辅助用药联合常规治疗用于乳腺癌患者,可提高治疗有效率、生活质量,提高免疫细胞指标CD3^(+)、CD4^(+)和CD4^(+)/CD8^(+)水平,降低肿瘤标志物CEA、CA125和CA153水平,减少白细胞减少、血小板减少、胃肠道反应、恶心呕吐和肝肾功能异常等情况的发生;但在降低免疫细胞指标CD8^(+)水平、减少骨髓抑制发生等方面无明显优势。OBJECTIVE:To evaluate the efficacy and safety of Xihuang pills/capsules in the clinical adjuvant treatment of breast cancer,so as to provide new ideas for the clinical treatment of breast cancer.METHODS:PubMed,Embase,the Cochrane Library,CNKI,SinoMed,Wanfang Data and VIP database were retrieved to collect the randomized controlled trials of Xihuang pills/capsules in the clinical adjuvant treatment of breast cancer from the establishment of the database to Dec.2nd,2022.The retrieved literature was screened and data was extracted,and Meta-analysis was performed by using RevMan 5.4.RESULTS:Twelve studies with a total of 1260 patients were included in this study,including 637 patients in the conventional treatment+Xihuang pills/capsules group and 623 patients in the conventional treatment group.Meta-analysis showed that compared with the conventional treatment group,the conventional treatment+Xihuang pills/capsules group had higher treatment effectiveness,higher quality of life score(Kanovsky score,FACT-B score),and higher levels of immune cell indicators CD3^(+),CD4^(+)and CD4^(+)/CD8^(+),lower levels of tumor markers CEA,CA153 and CA125,the differences were statistically significant(P<0.05).There was no significant difference in the levels of immune cell indicator CD8^(+)between two groups(P>0.05).In terms of safety,the leukopenia,thrombocytopenia,gastrointestinal reactions,nausea and vomiting and abnormal liver and kidney function in conventional treatment+Xihuang pills/capsules group were less than those in conventional treatment group,with statistically significant difference(P<0.05).However,there was no significant difference in the occurrence of myelosuppression between two groups(P>0.05).CONCLUSIONS:Xihuang pills,when used as an adjuvant in combination with conventional treatment for patients with breast cancer,can improve the efficacy,quality of life,increase the levels of immune cell indicators CD3^(+),CD4^(+)and CD4^(+)/CD8^(+),reduce the levels of tumor markers CEA,CA125 and CA153,and decrease the occurre

关 键 词：西黄丸 西黄胶囊 乳腺癌 META分析 

分 类 号：R932[医药卫生—生药学]